Top

Current Oncology Reports

Published in:

11-04-2024 | Urothelial Cancer | REVIEW

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma

Authors: Michael A. Liu, Jennifer W. Li, Karie Runcie

Published in: Current Oncology Reports | Issue 5/2024

Abstract

Purpose of Review

To summarize and evaluate the literature on treatment approaches for oligometastatic and locally recurrent urothelial cancer.

Recent Findings

There is no clear definition for oligometastatic urothelial cancers due to limited data. Studies focusing on oligometastatic and locally recurrent urothelial cancer have been primarily retrospective. Treatment options include local therapy with surgery or radiation, and generalized systemic therapy such as chemotherapy or immunotherapy.

Summary

Oligometastatic and locally recurrent urothelial cancers remain challenging to manage, and treatment requires an interdisciplinary approach. Systemic therapy is nearly always a component of current care in the form of chemotherapy, but the role of immunotherapy has not been explored. Consideration of surgical and radiation options may improve outcomes, and no studies have compared directly between the two localized treatment options. The development of new prognostic and predictive biomarkers may also enhance the treatment landscape in the future.

Amin HAA, Kobaisi MH, Samir RM. Schistosomiasis and bladder cancer in Egypt: truths and myths. Open Access Maced J Med Sci. 2019;7(23):4023–9. https://doi.org/10.3889/oamjms.2019.857.CrossRefPubMedPubMedCentral

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/jco.1995.13.1.8.CrossRefPubMed

Ogihara K, Kikuchi E, Watanabe K, Kufukihara R, Yanai Y, Takamatsu K, et al. Can urologists introduce the concept of “oligometastasis” for metastatic bladder cancer after total cystectomy? Oncotarget. 2017;8(67):111819–35. https://doi.org/10.18632/oncotarget.22911.CrossRefPubMedPubMedCentral

Franzese C, Francolini G, Nicosia L, Alongi F, Livi L, Scorsetti M. Stereotactic body radiation therapy in the management of oligometastatic and oligoprogressive bladder cancer and other urothelial malignancies. Clin Oncol (R Coll Radiol). 2021;33(1):50–6. https://doi.org/10.1016/j.clon.2020.07.008.CrossRefPubMed

Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, et al. Definition and diagnosis of oligometastatic bladder cancer: a Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. Eur Urol. 2023

Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Choueiri TK, Necchi A, et al. Improved 5-factor prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. J Urol. 2016;195(2):277–82. https://doi.org/10.1016/j.juro.2015.07.111.CrossRefPubMed

Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5. https://doi.org/10.1200/jco.2009.25.4599.CrossRefPubMed

Petrelli F, Ghidini A, Ghidini M, Bukovec R, Trevisan F, Turati L, et al. Better survival of patients with oligo-compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res. 2021;10

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder cancer, Version 3.2020. NCCN Clinical Practice Guidelines in Oncology J Natl Compr Canc Netw. 2020;18(3):329–54. https://doi.org/10.6004/jnccn.2020.0011.CrossRefPubMed

10.

Pisters LL, Westney L. The management of locally recurrent invasive bladder cancer following radical cystectomy. Semin Urol Oncol. 1996;14(2):112–9.PubMed

11.

Westney OL, Pisters LL, Pettaway CA, Tu SM, Pollack A, Dinney CP. Presentation, methods of diagnosis and therapy for pelvic recurrence following radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 1998;159(3):792–5.CrossRefPubMed

12.

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2023;41(22):3772–81.CrossRefPubMed

13.

Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, et al. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012;109(6):846–54. https://doi.org/10.1111/j.1464-410X.2011.10455.x.CrossRefPubMed

14.

Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser Hr, Markwalder R, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy. J Clin Oncol. 2003; 21(4):690–6

15.

Cagiannos I, Morash C. Surveillance strategies after definitive therapy of invasive bladder cancer. Can Urol Assoc J. 2009;3(6 Suppl 4):S237–42. https://doi.org/10.5489/cuaj.1205.CrossRefPubMedPubMedCentral

16.

Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am. 2003;30(4):777–89. https://doi.org/10.1016/s0094-0143(03)00061-2.CrossRefPubMed

17.

Zehnder P, Studer UE, Skinner EC, Thalmann GN, Miranda G, Roth B, et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 2013;112(2):E51–8. https://doi.org/10.1111/bju.12215.CrossRefPubMed

18.

Abe T, Minami K, Harabayashi T, Sazawa A, Chiba H, Kikuchi H, et al. Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol. 2020;50(2):206–13. https://doi.org/10.1093/jjco/hyz152.CrossRefPubMed

19.

Faltas BM, Gennarelli RL, Elkin E, Nguyen DP, Hu J, Tagawa ST. Metastasectomy in older adults with urothelial carcinoma: population-based analysis of use and outcomes. Urol Oncol. 2018;36(1):9.e11-9.e7. https://doi.org/10.1016/j.urolonc.2017.09.009.CrossRefPubMed

20.

Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M D Anderson experience. J Urol. 2004;171(1):145–8. https://doi.org/10.1097/01.ju.0000099823.60465.e6.CrossRefPubMed

21.

Iwamoto H, Izumi K, Shimura Y, Natsagdorj A, Maolake A, Takezawa Y, et al. Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res. 2016;36(10):5557–61. https://doi.org/10.21873/anticanres.11140.CrossRefPubMed

22.

Muilwijk T, Akand M, Van der Aa F, Dumez H, De Meerleer G, Van Raemdonck D, et al. Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Transl Androl Urol. 2020;9(3):1296–305. https://doi.org/10.21037/tau-19-624.CrossRefPubMedPubMedCentral

23.

Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49. https://doi.org/10.1016/s0022-5223(97)70397-0.CrossRefPubMed

24.

Zaghloul MS. Adjuvant and neoadjuvant radiotherapy for bladder cancer: revisited. Future Oncol. 2010;6(7):1177–91. https://doi.org/10.2217/fon.10.82.CrossRefPubMed

25.

Chalkidou A, Macmillan T, Grzeda MT, Peacock J, Summers J, Eddy S, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021;22(1):98–106. https://doi.org/10.1016/s1470-2045(20)30537-4.CrossRefPubMed

26.•

Aboudaram A, Chaltiel L, Pouessel D, Graff-Cailleaud P, Benziane-Ouaritini N, Sargos P, et al. Consolidative radiotherapy for metastatic urothelial bladder cancer patients with no progression and with no more than five residual metastatic lesions following first-line systemic therapy: a retrospective analysis. Cancers (Basel). 2023. 15(4). https://doi.org/10.3390/cancers15041161. This recent article is the largest retrospective study on radiotherapy for oligometastatic urothelial cancer, consisting of 91 patients from four comprehensive cancer centers from 2005 to 2018, which demonstrated a large overall (HR 0.47) and progression free (HR 0.49) survival benefit.

27.

Francolini G, Desideri I, Detti B, Di Cataldo V, Masi L, Caramia G, et al. Stereotactic radiotherapy in oligoprogressive and oligorecurrent urothelial cancer patients: a retrospective experience. Cancer Treat Res Commun. 2019;19:100124. https://doi.org/10.1016/j.ctarc.2019.100124.CrossRefPubMed

28.

Augugliaro M, Marvaso G, Ciardo D, Zerini D, Riva G, Rondi E, et al. Recurrent oligometastatic transitional cell bladder carcinoma: is there room for radiotherapy? Neoplasma. 2019;66(1):160–5. https://doi.org/10.4149/neo_2018_180522N333.CrossRefPubMed

29.

Nevens D, Jongen A, Kindts I, Billiet C, Deseyne P, Joye I, et al. Completeness of reporting oligometastatic disease characteristics in the literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature. Int J Radiat Oncol Biol Phys. 2022;114(4):587–95. https://doi.org/10.1016/j.ijrobp.2022.06.067.CrossRefPubMed

30.

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30. https://doi.org/10.1056/NEJMoa2002788.CrossRefPubMed

31.

Leonetti A, D’Abbiero N, Baldari G, Andreani S, Ruffini L, Viansone AA, et al. Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: a retrospective case series. Int J Urol. 2018;25(10):879–86. https://doi.org/10.1111/iju.13773.CrossRefPubMed

32.

Powles TB, Perez Valderrama B, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. LBA6 EV-302/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). Ann Oncol. 2023;34:S1340. https://doi.org/10.1016/j.annonc.2023.10.106.CrossRef

33.

van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N Engl J Med. 2023;389(19):1778–89. https://doi.org/10.1056/NEJMoa2309863.CrossRefPubMed

34.

Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere WR, Sarosdy MF, et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9. https://doi.org/10.1200/jco.2004.11.024.CrossRefPubMed

35.

Fischer-Valuck BW, Michalski JM, Mitra N, Christodouleas JP, DeWees TA, Kim E, et al. Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer. Cancer Med. 2019;8(8):3698–709. https://doi.org/10.1002/cam4.2102.CrossRefPubMedPubMedCentral

36.

Wishnow KI, Dmochowski R. Pelvic recurrence after radical cystectomy without preoperative radiation. J Urol. 1988;140(1):42–3. https://doi.org/10.1016/s0022-5347(17)41480-7.CrossRefPubMed

37.•

Ballas L, Wei O, Daneshmand S, Schuckman A, Djaladat H, Aron M, et al (2020) Chemoradiation for management of locally recurrent or residual bladder cancer: a case series and review of the literature Clin Genitourin Cancer 18 4 e473-e7. https://doi.org/10.1016/j.clgc.2019.12.016. This recent article involving a case series of five patients with locally recurrent urothelial cancer is the first to demonstrate the potential safety and efficacy of locoregional chemoradiation treatment in this setting.

Title: Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma
Authors: Michael A. Liu
Jennifer W. Li
Karie Runcie
Publication date: 11-04-2024
Publisher: Springer US
Keywords: Urothelial Cancer
Urothelial Cancer
Systemic Therapy
Cystectomy
Cytostatic Therapy
Published in: Current Oncology Reports / Issue 5/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01523-8

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2024

Perioperative Neurocognitive Function in Glioma Surgery

Current Trends and Challenges of Microbiome Research in Prostate Cancer

Immune Checkpoint Inhibitors in Geriatric Oncology

Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer

Advances in radionuclide therapies for neuroendocrine tumors